Navigation Links
Glivec Enhances Survival Rates In Leukemia

Glivec, a drug used to treat chronic myeloid leukemia has shown to improve the survival rates in 90 percent of patients with the cancer.// The National Institute for health and Clinical Excellence (NICE), which regulates drug approvals in the UK had only wanted to approve Glivec for advanced cases, but the drug has not proved itself in clinical trials.

CML is a common form of blood cancer, which arises due to a defect in the production of white blood cells. Glivec targets only the affected molecules and leaves the healthy ones unaffected. But it is an expensive drug and costs at least £14,000 per patient per year.

Results from the IRIS study showed that 93 percent of patients taking the drug in early stages did not progress to advanced stage. Also 83 percent had good survival rate of five years. Before the introduction of Glivec, CML had poor prognosis with survival rates of only four to six years.

Sandy Craine, from CML Support, who took part in the trial said, "I never would have believed I would be standing here today. Glivec helped save my life and I am grateful that I can pass on this message of hope to others diagnosed with this once devastating disease."

Professor Charles Craddock, director of Stem Cell Transplant Unit, Queen Elizabeth Hospital, Birmingham, added, "The significant success of Glivec in treating CML is an exciting model for the development of new treatments for other cancers."
'"/>




Page: 1

Related medicine news :

1. Glivec - New Hope For CMC Patients
2. Glivec the hot cancer drug from Novartis
3. Animal Fat Enhances Risk Of Stomach
4. Tiagabine Enhances Sleep Maintenance In Insomnia Patients
5. Simulated Heart Tissue Enhances Understanding of Arrhythmias And Defibrillator Failure
6. Study Claims That Chemo Before And After Surgery Enhances Survival Rates
7. Common Virus Enhances Cancer-Fighting Ability of Standard Chemotherapy Drugs
8. Haryana Enhances Nutritional Support for Women, Children
9. Loop Incision Treatment Enhances Premature Delivery Risk
10. Long-Term Survival can be Predicted by a Simple Lung Test
11. Hepatitis G May Boost HIV Survival
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/29/2016)... ... ... Spine Team Texas, a comprehensive spine physician group specializing in the treatment ... been invited to be a featured speaker at the Texas Society of the American ... 2016. , Dr. R. Scott McPherson, a physical medicine and rehabilitation specialist, will ...
(Date:4/29/2016)... ... ... Mobility Designed is redefining mobility with their patent pending crutch design. ... distributes body weight from the elbow to the forearm. In consumer tests, users ... other crutches. , Co-founders Max and Liliana Younger were inspired to design the crutches ...
(Date:4/29/2016)... ... April 29, 2016 , ... The Gluten-Free ... is pleased to announce the launch of the GFCP Scoop in ... more. The purpose of the GFCP Scoop site is to keep ...
(Date:4/29/2016)... ... ... Dr. Robert Mondavi, one of the dentists in Torrance , is now ... as more patients are discovering the many different ways they can change and improve ... to them and which ones might work for their smiles. , “One of ...
(Date:4/29/2016)... ... April 29, 2016 , ... Reltok Nasal Products proudly announces ... the head and neck/ear, nose and throat specialty, has added the KOTLER NASAL AIRWAY™ ... NASAL AIRWAY™ is a newly patented safety device secured by nasal surgeons onto ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 28, 2016  ValGenesis, Inc., the market ... (VLMS) today announced that a prominent world ... of chronic kidney failure has selected ValGenesis ... corporate validation process. The global medical device ... to manage their validation processes electronically. Upon ...
(Date:4/27/2016)... -- Hologic, Inc. (Nasdaq: HOLX ) announced ... second quarter ended March 26, 2016.  GAAP diluted ... and non-GAAP diluted EPS of $0.47 increased 14.6%.  ... reported basis, and 6.3% on a constant currency ... quarter, highlighted by 14.6% growth in non-GAAP EPS," ...
(Date:4/27/2016)... 2016   , ... Recurring Consumable Sales  Clinical sales grow 16% ... (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary ... the first quarter ended March 31, 2016 and provided ... its commercial strategy. First Quarter 2016 Revenue ...
Breaking Medicine Technology: